{"id":295331,"date":"2025-02-17T00:00:00","date_gmt":"2025-02-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0002-2022-biopharma-malignant-melanoma-current-treatment-treatment-sequencing-malignant\/"},"modified":"2026-03-31T10:26:58","modified_gmt":"2026-03-31T10:26:58","slug":"trsqon0002-2025-biopharma-malignant-melanoma-current-treatment-treatment-sequencing-malignant-melanoma-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0002-2025-biopharma-malignant-melanoma-current-treatment-treatment-sequencing-malignant-melanoma-us\/","title":{"rendered":"Malignant Melanoma &#8211; Current Treatment &#8211; Treatment Sequencing &#8211; Malignant Melanoma (US)"},"content":{"rendered":"<p><strong>KEY BENEFITS AND USES <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li><strong>Pinpoint<\/strong> current drug positioning and uptake in one snapshot to facilitate forecasting.<\/li>\n<li><strong>Drill down<\/strong> into physicians\u2019 treatment sequences and understand whom to position against or how to defend share.<\/li>\n<li><strong>Identify<\/strong> untapped treatment scenarios and key competitors to aid trial design.<\/li>\n<li><strong>Evaluate<\/strong> unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.<\/li>\n<li><strong>Discover<\/strong> untapped populations to expand product share and drive strategic decisions.<\/li>\n<\/ul>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Where is my product positioned vs. competitors in the treatment journey?<\/li>\n<li>What are surveyed physicians\u2019 most frequent treatment sequences? Who is benefiting, and how can I defend my asset\u2019s share and position?<\/li>\n<li>What are the market-relevant treatment scenarios according to surveyed prescribers?<\/li>\n<li>Where are the untapped business opportunities that I can capitalize on?<\/li>\n<li>How can I optimize trial design and ensure a competitive edge for my pipeline asset?<\/li>\n<\/ul>\n<p><strong>GEOGRAPHY<\/strong><\/p>\n<p>United States<\/p>\n<p><strong>PRIMARY MARKET RESEARCH<\/strong><\/p>\n<p>Survey of 100 U.S. medical oncologists<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and Clarivate oncology experts\u2019 assumptions.<\/p>\n","protected":false},"template":"","class_list":["post-295331","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295331\/revisions"}],"predecessor-version":[{"id":398572,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295331\/revisions\/398572"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}